We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

105 hedge funds and large institutions have $328M invested in UroGen Pharma in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 18 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 18

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

32% more capital invested

Capital invested by funds: $248M → $328M (+$79.7M)

12.29% more ownership

Funds ownership: 58.53% → 70.82% (+12%)

4% more funds holding

Funds holding: 101 → 105 (+4)

2% more call options, than puts

Call options by funds: $344K | Put options by funds: $336K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
105
Holders Change
+4
Holders Change %
+3.96%
% of All Funds
1.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
16
Increased
50
Reduced
18
Closed
12
Calls
$344K
Puts
$336K
Net Calls
+$8K
Net Calls Change
-$525K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$20.8M
2
RI
RTW Investments
New York
+$11.3M
3
Morgan Stanley
Morgan Stanley
New York
+$10.4M
4
BlackRock
BlackRock
New York
+$6.77M
5
Millennium Management
Millennium Management
New York
+$1.96M

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$5.21M
2
CI
Clal Insurance
Israel
-$3.11M
3
EI
EAM Investors
California
-$2.39M
4
LCM
Laurion Capital Management
New York
-$1.69M
5
CSS
Cubist Systematic Strategies
Connecticut
-$1.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$1.96M +$137K +10,541 +9%
Point72 Asset Management
27
Point72 Asset Management
Connecticut
$1.89M -$1.06M -81,733 -39%
Cerity Partners
28
Cerity Partners
New York
$1.88M +$1.63M +125,226 New
Goldman Sachs
29
Goldman Sachs
New York
$1.71M +$786K +60,574 +113%
Wellington Management Group
30
Wellington Management Group
Massachusetts
$1.57M +$448K +34,537 +49%
MIH
31
Meitav Investment House
Israel
$1.37M – – –
Renaissance Technologies
32
Renaissance Technologies
New York
$1.37M -$896K -69,000 -43%
N
33
Nuveen
North Carolina
$1.25M +$257K +19,785 +31%
AC
34
Annandale Capital
Texas
$1.23M – – –
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$1.17M +$574K +44,240 +132%
Ameriprise
36
Ameriprise
Minnesota
$1.09M -$171K -13,148 -15%
Bank of America
37
Bank of America
North Carolina
$1.07M +$368K +28,326 +65%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.05M +$160K +12,298 +21%
RHJA
39
Rice Hall James & Associates
California
$1.05M -$68.6K -5,288 -7%
Charles Schwab
40
Charles Schwab
California
$943K +$214K +16,486 +36%
AI
41
Atom Investors
Texas
$902K +$578K +44,505 +284%
Squarepoint
42
Squarepoint
New York
$895K +$775K +59,690 New
Connor, Clark & Lunn Investment Management (CC&L)
43
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$690K +$210K +16,211 +54%
CBA
44
Coastal Bridge Advisors
Connecticut
$566K -$9.74K -750 -2%
Barclays
45
Barclays
United Kingdom
$561K +$441K +33,946 +992%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$521K +$102K +7,842 +29%
BRA
47
Bender Robert & Associates
California
$521K – – –
JF
48
Jump Financial
Illinois
$500K +$48.3K +3,720 +13%
SAM
49
Shikiar Asset Management
New York
$499K – – –
Marshall Wace
50
Marshall Wace
United Kingdom
$428K +$22.5K +1,731 +6%
1
2
3 4 5

URGN Hedge Fund Activity: Q4 2023 in Review

105 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2023, worth a combined $328M — up 32% from $248M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new URGN positions and 12 closed out — a net gain of 4 holders — while 50 added to existing stakes and 18 trimmed.

The largest buyer was RA Capital Management, adding an estimated $20.8M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $5.21M sold.

  • 105 institutional investors held UroGen Pharma (URGN) as of Q4 2023, up from 101 in Q3 2023.
  • Funds reported $328M of UroGen Pharma stock for Q4 2023, up 32% quarter-over-quarter.
  • 16 funds opened new UroGen Pharma positions in Q4 2023 and 12 closed out, a net change of +4 holders.
  • The largest UroGen Pharma buyer in Q4 2023 was RA Capital Management, an estimated $20.8M added.
  • The largest UroGen Pharma seller in Q4 2023 was Soleus Capital Management, an estimated $5.21M sold.

Based on aggregated 13F filings for Q4 2023.